Displaying publications 1 - 20 of 277 in total

Abstract:
Sort:
  1. Malayan Medical Journal, 1933;8:119-20.
    Matched MeSH terms: Antimalarials
  2. Wallace RB
    Matched MeSH terms: Antimalarials
  3. Duncan D
    Matched MeSH terms: Antimalarials
  4. Niven JC
    Matched MeSH terms: Antimalarials
  5. Field JW
    Matched MeSH terms: Antimalarials
  6. Field JW, Niven JC, Guest C, Byron FE
    Matched MeSH terms: Antimalarials
  7. Barrowman B
    Malayan Medical Journal, 1933;8:257-60.
    Matched MeSH terms: Antimalarials
  8. Barrowman B
    Malayan Medical Journal, 1933;8:163-75.
    Matched MeSH terms: Antimalarials
  9. Jayaraman SD, Ismail S, Nair NK, Navaratnam V
    J Chromatogr B Biomed Sci Appl, 1997 Mar 07;690(1-2):253-7.
    PMID: 9106050
    A method is described for the determination of pyronaridine in plasma using high-performance liquid chromatography with fluorescence detection. The method involves liquid-liquid extraction with phosphate buffer (pH 6.0, 0.05 M) and diethyl ether-hexane (70:30%, v/v) and chromatographic separation on a C18 column (Nucleosil, 250 x 4.6 mm I.D., 5 microns particle size) with acetonitrile-0.05 M phosphate buffer pH 6.0 (60:40%, v/v) as the mobile phase (1 ml/min) and detection by fluorescence (lambda ex = 267 nm, lambda em = 443 nm). The detector response is linear up to 1000 ng and the overall recoveries of pyronaridine and quinine were 90.0 and 60.3%, respectively. The assay procedure was adequately sensitive to measure 10 ng/ml pyronaridine in plasma samples with acceptable precision (< 15% C.V.). The method was found to be suitable for use in clinical pharmacological studies.
    Matched MeSH terms: Antimalarials/blood*; Antimalarials/pharmacokinetics
  10. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P
    Clin Pharmacokinet, 2000 Oct;39(4):255-70.
    PMID: 11069212
    Various compounds of the artemisinin family are currently used for the treatment of patients with malaria worldwide. They are characterised by a short half-life and feature the most rapidly acting antimalarial drugs to date. They are increasingly being used, often in combination with other drugs, although our knowledge of their main pharmacological features (including their absorption, distribution, metabolism and excretion) is still incomplete. Such data are particularly important in the case of combinations. Artemisinin derivatives are converted primarily, but to different extents, to the bioactive metabolite artenimol after either parenteral or gastrointestinal administration. The rate of conversion is lowest for artelinic acid (designed to protect the molecule against metabolism) and highest for the water-soluble artesunate. The absolute and relative bioavailability of these compounds has been established in animals, but not in humans, with the exception of artesunate. Oral bioavailability in animals ranges, approximately, between 19 and 35%. A first-pass effect is highly probably for all compounds when administered orally. Artemisinin compounds bind selectively to malaria-infected erythrocytes to yet unidentified targets. They also bind modestly to human plasma proteins, ranging from 43% for artenimol to 81.5% for artelinic acid. Their mode of action is still not completely understood, although different theories have been proposed. The lipid-soluble artemether and artemotil are released slowly when administered intramuscularly because of the 'depot' effect related to the oil formulation. Understanding the pharmacokinetic profile of these 2 drugs helps us to explain the characteristics of the toxicity and neurotoxicity. The water-soluble artesunate is rapidly converted to artenimol at rates that vary with the route of administration, but the processes need to be characterised further, including the relative contribution of pH and enzymes in tissues, blood and liver. This paper intends to summarise contemporary knowledge of the pharmacokinetics of this class of compounds and highlight areas that need further research.
    Matched MeSH terms: Antimalarials/metabolism; Antimalarials/pharmacokinetics*; Antimalarials/therapeutic use
  11. Jolley PGE
    Malayan Medical Journal, 1932;7:129-131.
    Matched MeSH terms: Antimalarials
  12. Wallace RB
    Malayan Medical Journal, 1934;9:146-54.
    Matched MeSH terms: Antimalarials
  13. WILSON T, EDESON JF
    Med J Malaya, 1958 Mar;12(3):471-99.
    PMID: 13565021
    Matched MeSH terms: Antimalarials/therapeutic use*
  14. WILSON T, EDESON JF
    Med J Malaya, 1957 Mar;11(3):190-200.
    PMID: 13476996
    Matched MeSH terms: Antimalarials/therapeutic use*
  15. EDESON JF, TURNER LH, LAING AB
    Med J Malaya, 1955 Jun;9(4):260-4.
    PMID: 13253125
    Matched MeSH terms: Antimalarials/therapeutic use*
  16. EDESON JF, WILSON T, TURNER LH, LAING AB
    Med J Malaya, 1955 Jun;9(4):252-9.
    PMID: 13253124
    Matched MeSH terms: Antimalarials/therapeutic use*
  17. Aziz MY, Hoffmann KJ, Ashton M
    PMID: 28863865 DOI: 10.1016/j.jchromb.2017.06.035
    PURPOSE: This study aimed to develop a sensitive, quantitative assay for the antimalarial piperaquine (PQ) and its metabolites M1 and M2 in human plasma.

    RESULTS: Analytes were gradiently separated on a C18 column and detected with a Sciex API 4000 MS/MS with an ESI source operated in the positive ion mode with deuterated PQ as internal standard. The response was linear in the range 3.9-2508nM with a runtime of 7.0min per sample. The method was applied to clinical samples from healthy volunteers.

    CONCLUSION: This LC-MS/MS method for the simultaneous quantitation of PQ and two of its metabolites in plasma may prove helpful for assessment of metabolite safety issues in vivo.

    Matched MeSH terms: Antimalarials/blood*; Antimalarials/metabolism; Antimalarials/pharmacokinetics; Antimalarials/chemistry
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links